Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_0003 |
| Primary information | |
|---|---|
| B3PDB ID | b3pdb_0003 |
| Peptide Name | K16ApoE |
| PEPTIDE SEQUENCE (1-letter) | NA |
| PEPTIDE SEQUENCE (3-letter) | NA |
| N-terminal modification | NA |
| C-terminal modification | NA |
| Chemical modification | NA |
| Peptide Length | 16 |
| Conformation | NA |
| Peptide Nature | Cationic |
| Source/Origin of peptide | Chemically synthesized |
| SMILES | NA |
| Cell Line | hCMEC/D3 monolayers |
| In vitro CONCENTRATION | NA |
| In vitro METHOD | Laser confocal microscopy |
| In vitro RESULT | The uptake of AF647-K16ApoE-targeted nanoparticles was substantially greater than the AF647-targeted |
| ANIMAL MODEL | WT mice |
| In vivo CONCENTRATION | 75 μg/μL |
| In vivo MODE OF DELIVERY | NA |
| In vivo METHOD | Injected into the femoral vein of 2- year-old APP transgenic (Tg2576) mice |
| In vivo RESULT | The K16ApoE-targeted nanoparticles showed 8- to 10-fold higher accumulation in various brain regions |
| ACTION | It enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. |
| TRANSPORT TYPE | Transcytosis |
| SUBCELLULAR LOCALISATION | intracellular |
| COMBINATION | It is given in the combination with IgG4.1 |
| PHYSICAL CONDITION | Alzheimer’s disease |
| RESPONSE | NA |
| RESULT | NA |
| LABEL | NA |
| PMID | 30300748 |